BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly to Expand Zepbound Availability with Higher Doses
Eli Lilly to Expand Zepbound Availability with Higher Doses
11
1
Pharmaceutical heavyweight Eli Lilly (LLY) will introduce higher-dose variants of its blockbuster weight-loss drug Zepbound through its LillyDirect platform, with shipments commencing in August. The 12.5mg and 15mg doses will be priced at $499 monthly for self-paying patients, while healthcare providers gain prescribing access starting July 7.
The MOVE follows Lilly's 2023 rollout of lower-dose vials via LillyDirect, later discounted in February to compete with Novo Nordisk (NVO). Pricing remains contentious—while some patients pay as little as $25 monthly through insurance, the drug's $1,059 list price previously sparked accusations of price gouging from consumers and legislators alike.
By:
Previous
Visa Boosts USDC Adoption in CEMEA via Yellow Card Stablecoin Partnership
Next
Empire Stock Surges on Strong Q4 Earnings and Consumer Spending Resilience
